ICON Public Limited (NASDAQ:ICLR – Free Report) – Research analysts at William Blair raised their FY2024 EPS estimates for ICON Public in a report issued on Wednesday, January 15th. William Blair analyst M. Smock now forecasts that the medical research company will post earnings of $13.55 per share for the year, up from their previous estimate of $13.40. William Blair has a “Outperform” rating on the stock. The consensus estimate for ICON Public’s current full-year earnings is $13.41 per share. William Blair also issued estimates for ICON Public’s FY2025 earnings at $13.33 EPS.
ICLR has been the subject of a number of other reports. The Goldman Sachs Group lowered their price target on shares of ICON Public from $370.00 to $280.00 and set a “buy” rating for the company in a report on Friday, October 25th. JPMorgan Chase & Co. lowered their price objective on shares of ICON Public from $375.00 to $280.00 and set an “overweight” rating for the company in a research note on Friday, October 25th. Robert W. Baird cut their target price on ICON Public from $249.00 to $225.00 and set a “neutral” rating on the stock in a research note on Wednesday, November 20th. Leerink Partners reaffirmed an “outperform” rating and set a $255.00 price target (down previously from $270.00) on shares of ICON Public in a research report on Tuesday, November 19th. Finally, Evercore ISI cut their price objective on ICON Public from $360.00 to $350.00 and set an “outperform” rating on the stock in a research report on Tuesday, October 8th. Four investment analysts have rated the stock with a hold rating, eleven have assigned a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat, ICON Public presently has a consensus rating of “Moderate Buy” and an average target price of $287.00.
ICON Public Price Performance
ICLR opened at $198.11 on Monday. The company has a debt-to-equity ratio of 0.35, a current ratio of 1.34 and a quick ratio of 1.34. ICON Public has a 1 year low of $183.38 and a 1 year high of $347.72. The stock’s 50 day simple moving average is $209.43 and its 200 day simple moving average is $266.68. The firm has a market cap of $16.34 billion, a price-to-earnings ratio of 22.09, a PEG ratio of 1.59 and a beta of 1.20.
ICON Public (NASDAQ:ICLR – Get Free Report) last announced its quarterly earnings data on Wednesday, October 23rd. The medical research company reported $3.35 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $3.72 by ($0.37). The business had revenue of $2.03 billion during the quarter, compared to analysts’ expectations of $2.13 billion. ICON Public had a net margin of 9.00% and a return on equity of 11.91%. ICON Public’s revenue for the quarter was down 1.2% on a year-over-year basis. During the same period last year, the company posted $3.10 EPS.
Institutional Trading of ICON Public
A number of large investors have recently made changes to their positions in the stock. Park Place Capital Corp lifted its holdings in shares of ICON Public by 281.4% during the 4th quarter. Park Place Capital Corp now owns 225 shares of the medical research company’s stock valued at $47,000 after buying an additional 166 shares during the period. GAMMA Investing LLC boosted its position in ICON Public by 64.0% in the fourth quarter. GAMMA Investing LLC now owns 433 shares of the medical research company’s stock worth $91,000 after purchasing an additional 169 shares during the last quarter. EverSource Wealth Advisors LLC grew its stake in shares of ICON Public by 39.2% during the 2nd quarter. EverSource Wealth Advisors LLC now owns 394 shares of the medical research company’s stock valued at $129,000 after purchasing an additional 111 shares during the period. Whittier Trust Co. of Nevada Inc. increased its position in shares of ICON Public by 23.1% during the 3rd quarter. Whittier Trust Co. of Nevada Inc. now owns 511 shares of the medical research company’s stock valued at $147,000 after purchasing an additional 96 shares during the last quarter. Finally, First Horizon Advisors Inc. boosted its holdings in shares of ICON Public by 33.9% in the third quarter. First Horizon Advisors Inc. now owns 597 shares of the medical research company’s stock worth $172,000 after buying an additional 151 shares during the last quarter. 95.61% of the stock is currently owned by institutional investors.
ICON Public Company Profile
ICON Public Limited Company, a clinical research organization, provides outsourced development and commercialization services in Ireland, rest of Europe, the United States, and internationally. The company specializes in the strategic development, management, and analysis of programs that support various stages of the clinical development process from compound selection to Phase I-IV clinical studies.
Read More
- Five stocks we like better than ICON Public
- How to Calculate Retirement Income: MarketBeat’s Calculator
- 3 Stocks to Gain From Donald Trump’s External Revenue Service
- Basic Materials Stocks Investing
- AMD: Loop Capital’s Buy Rating Reinforces Investor Confidence
- 3 Must-Buy Warren Buffett Stocks for Volatile Times
- Momentum Is Building for Qualcomm to Have a Strong Run in 2025
Receive News & Ratings for ICON Public Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ICON Public and related companies with MarketBeat.com's FREE daily email newsletter.